Debbie Rigby rounds up the latest in research news
This study is a prospective cohort study of treated hypertensive patients aged ≥60 years. Consumption of sleeping pills was prospectively linked to an increased number of antihypertensive drugs. The authors concluded “sleeping pill use” might be an indicator of future needs of antihypertensive treatment, and a warning indicator to investigate underlying sleep disorders or unhealthy lifestyles.
Geriatrics & Gerontology International 2019.
A retrospective cohort study has confirmed the importance of providing DOAC anticoagulation in patients with NVAF. In this cohort of 18,901 newly diagnosed patients with NVAF, DOAC therapy was associated with a significantly lower risk of death compared with no oral anticoagulation. Death occurred at the rate of 7.6% per year in the DOAC-treated group compared with 11.1% per year in the non-anticoagulated patient group. DOAC therapy was associated with 31% lower risk for all-cause mortality.
Data from smoking cessation consultations were obtained for 66 consecutive patients seen by one practice pharmacist. The observed abstinence rate was comparable or better than those obtained by practice nurses, community pharmacists and outpatient pharmacists, indicating the general practice pharmacist provided an effective smoking cessation intervention.
Journal of Smoking Cessation. Published online 5 April 2019.
An evaluation of 7 RCTs has concluded that SGLT-2 inhibitors provoke an average reduction of systolic/diastolic BP 3.62/1.70 mmHg in 24-h ambulatory BP. This BP-lowering effect remains unmodified regardless of the dose of SGLT-2 inhibitor and is comparable with BP-lowering efficacy of low-dose hydrochlorothiazide. BP lowering with SGLT-2 inhibition was more potent during daytime than during nighttime.
Diabetes Care 2019 Apr; 42(4): 693-700.